Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder. (3rd October 2018)

• Record Type: Journal Article
• Authors: Hebbrecht, Kaat; Morrens, Manuel; Neels, Hugo; Roosens, Laurence; Sabbe, Bernard G. C.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 14:Number 10(2018)
• Page Start: 999
• Page End: 1005
• Publication Date: 2018-10-03
• Subjects: Antipsychotic -- aripiprazole -- bipolar disorder -- long-acting injectable -- LAI; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2018.1515911
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered : This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion : AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options.